Group A | Â | Â |
 Suitable for surgery—but at higher risk of complications compared to group B (potentially eligible for SABRTooth) | ▪ CPEX—VO2 max 10–15 L/kg/min ▪ ISWT—walk 250–400 m ▪ Mortality risk from Nottingham score: 6–20 % at 90 days | The patient can be approached for the trial if they meet one or more of these criteria |
Group B | Â | Â |
 Suitable for surgery—lower risk of complications | ▪ CPEX—VO2 max >15 L/kg/min, anaerobic threshold ▪ ISWT—walk >400 m and without significant desaturation ▪ Predicted post-operative FEV1 > 50 % ▪ Mortality risk from Nottingham score <6 % at 90 days for lobectomy (it is not anticipated that patients will need a pneumonectomy in this group of peripheral cancers). | Not suitable for the trial |
Group C | Â | Â |
 Unsuitable for surgery as predicted risk of complications is too high | ▪ CPEX—VO2 max <10 L/kg/min ▪ ISWT—walk <250 m and significant desaturation ▪ Pre-operative FEV1 < 30 % ▪ Mortality risk from Nottingham score >20 % at 90 days for lobectomy (it is not anticipated that patients will need a pneumonectomy in this group of peripheral cancers). ▪ Reduced ejection fraction (e.g. <40 %) or evidence of ongoing myocardial ischemia ▪ Recent cerebrovascular event (e.g. within 3 months of planned surgery) | Not suitable for the trial |